You are here: Home: LCU 3 | 2007: Mark A Socinski, MD - Select Publications

SELECT PUBLICATIONS

Azzoli CG et al. A phase II tolerability study of cisplatin plus docetaxel as adjuvant chemotherapy for resected non-small cell lung cancer. J Thorac Oncol 2007;2(7):638-44. Abstract

Clark GM et al. Smoking history and epidermal growth factor receptor expression as predictors of survival benefit from erlotinib for patients with non-small-cell lung cancer in the National Cancer Institute of Canada Clinical Trials Group study BR.21. Clin Lung Cancer 2006;7(6):389-94. Abstract

Fehrenbacher L et al. A phase II, multicenter, randomized clinical trial to evaluate the efficacy and safety of bevacizumab in combination with either chemotherapy (docetaxel or pemetrexed) or erlotinib hydrochloride compared with chemotherapy alone for treatment of recurrent or refractory non-small cell lung cancer. Proc ASCO 2006;Abstract 7062.

Fossella F et al. Randomized, multinational, phase III study of docetaxel plus platinum combinations versus vinorelbine plus cisplatin for advanced non-small-cell lung cancer: The TAX 326 study group. J Clin Oncol 2003;21(16):3016-24. Abstract

Hawkins MJ et al. Study of three weekly nab-paclitaxel regimens in combination with carboplatin as first-line therapy in advanced non-small cell lung cancer (NSCLC). Proc ASCO 2007;Abstract 7659.

Herbst RS et al. Phase I/II trial evaluating the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-1/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer. J Clin Oncol 2005;23(11):2544-55. Abstract

Herbst RS et al. TRIBUTE: A phase III trial of erlotinib hydrochloride (OSI-774) combined with carboplatin and paclitaxel chemotherapy in advanced non-small-cell lung cancer. J Clin Oncol 2005b;23(25):5892-9. Abstract

Manegold C et al. Randomised, double-blind multicentre phase III study of bevacizumab in combination with cisplatin and gemcitabine in chemotherapy-naïve patients with advanced or recurrent non-squamous non-small cell lung cancer (NSCLC): BO17704. Proc ASCO 2007;Abstract LBA7514.

Reynolds C et al. An open-label, phase II trial of nanoparticle albumin bound paclitaxel (nab-paclitaxel), carboplatin, and bevacizumab in first-line patients with advanced non-squamous non-small cell lung cancer (NSCLC). Proc ASCO 2007;Abstract 7610.

Sandler A et al. Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med 2006;355(24):2542-50. Abstract

Stinchcombe TE et al. Feasibility of adjuvant carboplatin/docetaxel (C/D) in patients (pts) with resected stage I-IIIB non-small cell lung cancer (NSCLC): Preliminary report of a phase II trial. Proc ASCO 2007;Abstract 18069.

Subramanian J, Govindan R. Lung cancer in never smokers: A review. J Clin Oncol 2007;25(5):561-70. Abstract

Table of Contents

Top of Page